Association of Protocol Design‐Related Factors With Enrollment Duration in Clinical Trials

Read full text Summarise with VIRAT
Authors: Hiroaki Tsuchiya, Miwa Sekine, Yuji Nishizaki, Noriko Hida, Takehiko Sambe, Shoji Sanada, Toshio Naito
Cited by: 0
References: 41

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Patient enrollment is a critical factor in the success of clinical trials; however, many trials fail to recruit participants within a planned timeline. Protocol design is a key barrier to efficient recruitment. However, few studies have quantitatively evaluated the association between protocol design and enrollment duration across various disease areas and time periods. We conducted a cross-sectional study using data from ClinicalTrials.gov and another related database. Industry-sponsored phase 2 and 3 drug trials completed between January 2017 and September 2024 were included. Key variables related to the protocol design were extracted from trial protocols and database entries. The enrollment duration was estimated using the trial start dates, primary completion dates, and outcome time frames. Multiple linear regression analyses were conducted to identify factors associated with enrollment duration, including comparisons between the pre- and post-COVID-19 pandemic periods. In total, 1286 trials met the inclusion criteria. Multiple linear regression identified three variables significantly associated with a longer enrollment duration: number of original enrollments (p = 0.023), number of inclusion criteria (p < 0.001), and days of assessment (p = 0.013). Before the pandemic, the number of assessment days was the primary factor, while after the pandemic, the number of inclusion criteria had the strongest association. This study demonstrated that the enrollment duration was significantly influenced by protocol design features. To improve recruitment efficiency, careful consideration of the inclusion criteria, assessment burden, and enrollment targets is essential during trial planning. Causal relationships should be interpreted cautiously and further examined in future research.

Fields of Study & Subjects

Ethics in Clinical Research Statistical Methods in Clinical Trials Pharmaceutical industry and healthcare

Publication details

Journal / source
Clinical and Translational Science
Volume
19
Issue
4
Pages
e70529–e70529
Publication date
22 March 2026
Language
EN